slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 204,721-204,750
Pages 10,126
Rows per page 30
Component
204,721-204,750 of 303,780
30
Includes a sentiment analysis gauge showing a 'Buy' rating.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Action1 hit
02
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
04
The slide illustrates the self-assembly of Phosphatidylserine (PS) and Calcium ions into a cochleate structure.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
05
The slide uses a biological process diagram to illustrate how LNCs (Lipid Nanocochleates) leverage PS to enter cells.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
06
The slide uses a comparative structure to explain two distinct biological pathways for drug delivery.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
07
Uses a visual arrow-based timeline to show progression.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
08
The slide uses a checkmark/cross system to visually demonstrate the superiority of LNCs.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
09
The slide uses a Gantt-style chart to map drug programs against development stages.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
11
The diagram uses a hub-and-spoke model to define the 'ideal' product profile.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
12
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution1 hit
13
Includes medical imagery of fungal cells and brain infection.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
14
The slide details the dosing regimens for different cohorts over induction and consolidation phases.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
The chart uses a vertical dotted line at 0.2 to denote a clinical efficacy threshold.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction1 hit
17
Includes n/N counts and specific clinical trial footnotes regarding patient outcomes and data status.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction1 hit
18
Each patient is represented by a timeline showing rapid decline in fungal load from screening to final visit day.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction1 hit
20
Clinical trial design diagram showing randomization into three arms with specific drug regimens over a 10-week period.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
The slide uses a chevron-based timeline to illustrate the lifecycle management strategy.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
Includes MIC comparison, tissue fungal burden (lung/brain), and survival curves.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The slide uses a map of the US to anchor the revenue projection and a list of four comparable deals to establish market precedent.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Market Sizing1 hit
24
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
26
Data presented as three distinct charts: line graph for weight, dot plot for congestion, and dot plot for viral titers.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
27
The slide highlights a $2.75M upfront payment and the strategic synergy between Matinas' LNC platform and BioNTech's mRNA expertise.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
28
The slide emphasizes long-term exclusivity through both patent filings and regulatory status (QIDP/ODD).Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
30
Uses checkmarks for completed items and circular arrows for upcoming/potential items.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
01
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
02
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
03
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
04
The slide presents preliminary financial data for the third quarter of 2022, including income statement components and key balance sheet items.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
05
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
01
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit